Test Price
5,600 AEDโ Home Collection Available
NGS Homologous Recombination Deficiency (HRD) Panel in UAE | 5,600 AED
Executive Summary & Core Metrics
UAE Trusted Diagnostic Excellence
- Accuracy Guarantee: 99.9% Analytical Sensitivity & 99.5% Specificity via ISO 9001:2015 Accredited NGS Processing.
- Specimen Logistics: Secure Medical Courier Solid Tissue Specimen Retrieval โ the FFPE tumour block is collected from the referring hospital pathology archive via temperature-controlled courier; a matched peripheral blood sample is obtained at the same facility.
- Clinical Guidance: Telephonic Post-Test Clinical Guidance with a Consultant Medical Geneticist for comprehensive result interpretation and family risk counselling.
- Insurance: Direct Billing Verification via WhatsApp +971 54 548 8731.
Test Overview & Methodology
The NGS Homologous Recombination Deficiency (HRD) Panel is a comprehensive genomic assessment that evaluates both somatic and germline mutations across 40+ homologous recombination repair (HRR) genes. This test identifies HRD status โ including BRCA1/2, RAD51, PALB2, ATM, and other key pathway members โ to guide PARP inhibitor therapy eligibility and inform hereditary cancer risk assessment. The analysis uses whole exome capture coupled with deep next-generation sequencing and is validated against GIAB and Promega proficiency standards for high-confidence variant calling.
| Feature | Our HRD Panel | Closest Alternative |
|---|---|---|
| Genetic Precision | NGS-based full HRR gene panel (40+ genes) with GIAB/Promega proficiency | Limited single-gene BRCA1/2 test |
| Analytical Sensitivity | 99.9% (validated library preparation with orthogonal confirmation) | ~95% for single-gene Sanger sequencing |
| Turnaround Time | 4โ6 weeks (comprehensive bioinformatics including genomic scar scoring) | 4โ6 weeks for two-gene targeted test |
| Clinical Utility | Direct PARP inhibitor eligibility, genomic instability score, hereditary cancer counselling | Restricted to BRCA mutation status only |
Physician Insight & Safety Protocols
Lina Osama Zaki Quteineh, Consultant Medical Genetics | DHA 9294403: "The comprehensive HRD panel provides a detailed view of the tumour's genomic instability landscape, which is essential for identifying patients who will derive the greatest benefit from PARP inhibitor therapy. A positive HRD score expands treatment options across ovarian, breast, pancreatic, and prostate cancers. However, this assay must always be interpreted alongside histopathology, disease stage, and prior treatment history. A negative result does not rule out platinum sensitivity and should never delay standard oncological care."
Important Medication Advisory
Do not discontinue, alter, or postpone any prescribed oncological therapies solely on the basis of pending HRD test results. This genomic assay is a complementary diagnostic tool intended to inform treatment planning in conjunction with the full clinical picture. It is not a substitute for standard-of-care monitoring, imaging surveillance, or ongoing multidisciplinary management.
Clinical Exclusion Criteria & Safety Precautions
- Patients who have received a blood transfusion or allogeneic bone marrow transplant within the preceding 6 weeks.
- FFPE tumour blocks with less than 20% tumour cellularity or insufficient tissue volume for adequate nucleic acid extraction.
- Pregnancy: genetic counselling is mandatory before proceeding; treatment decisions should be deferred until postpartum unless urgent clinical circumstances require multidisciplinary deliberation.
- Emergency Red Flags: Acute chest pain, uncontrolled haemorrhage, rapid neurological deterioration, or signs of tumour lysis syndrome require immediate emergency department evaluation. Do not await test results in such scenarios.
Patient FAQ & Clinical Guidance
1. Why do I need to provide both a blood sample and a tumour block for this HRD test?
Paired blood and FFPE tumour specimens allow our laboratory to differentiate inherited (germline) mutations from those acquired only in the tumour (somatic). This distinction is essential for accurate PARP inhibitor eligibility assessment and for determining whether family members may benefit from cascade genetic testing.
2. How long will it take to receive my results, and what happens afterward?
Results are reported within 4โ6 weeks. A post-test telephonic consultation with a Consultant Medical Geneticist is scheduled to explain the findings, discuss implications for treatment and family members, and coordinate with your oncology team for any recommended follow-up actions.
3. Is the HRD Panel covered by health insurance in the UAE?
Many UAE insurers cover the HRD Panel when it is prescribed by an oncologist for PARP inhibitor treatment planning. Our team performs a complimentary pre-test insurance verification via WhatsApp +971 54 548 8731 and assists with direct billing where applicable.
UAE Regulatory & Data Privacy Adherence
Your genomic data is protected under UAE law. DNA Labs UAE operates in full compliance with Federal Decree-Law No. 45 of 2021 on Personal Data Protection (PDPL) and Federal Law No. 2 of 2019 Concerning the Use of Information and Communication Technology in Health Fields. All genetic information is encrypted, stored on secure servers within the UAE, and accessed only by authorized clinical personnel for the sole purpose of diagnostic interpretation. No data is shared with third parties without your explicit written consent.
Clinical & Logistical Metadata
| Test Name | NGS Homologous Recombination Deficiency (HRD) Panel |
| Price (AED) | 5,600 AED |
| Turnaround Time | 4โ6 Weeks |
| Sample Type / Matrix | Blood & Formalin-Fixed Paraffin-Embedded (FFPE) Tumour Block โ Archival Tissue Specimen |
| Methodology Used | Next-Generation Sequencing (NGS) โ Whole Exome Capture with 40+ HRR Gene Panel (BRCA1/2, RAD51, PALB2, ATM, and others). Validated to GIAB and Promega proficiency standards. |
| ICD-10-CM Code | C56.9 (Malignant neoplasm of ovary) |
| LOINC Code | 97505-7 |
| DHA Facility License & Laboratory Address | DHA License 1143 | Premises 105, Floor 1, Building 33, Dubai Healthcare City, Dubai, UAE โ DNA Labs UAE |
ุฏุนู ุซูุงุฆู ุงููุบุฉ ู ุชุงุญ
ุงูุชุญูู ู ู ุงูุชุบุทูุฉ ุงูุชุฃู ูููุฉ
Check Insurance Coverage Instantly
Stop the guesswork. Send a photo of your Insurance Card and Doctor's Prescription to our DHA-Certified Verification Team on WhatsApp.
ุชููู ุนู ุงูุชุฎู ูู. ุฃุฑุณู ุตูุฑุฉ ู ู ุจุทุงูุฉ ุงูุชุฃู ูู ููุตูุฉ ุงูุทุจูุจ ุฅูู ูุฑูู ุงูุชุญูู ุงูู ุนุชู ุฏ ู ู ููุฆุฉ ุงูุตุญุฉ ุจุฏุจู ุนุจุฑ ุงููุงุชุณุงุจ. ุงุญุตู ุนูู ุชุญุฏูุซ ุงูุญุงูุฉ ูู ุฏูุงุฆู.
Available in Arabic, English, Hindi & Urdu
ISMS 27001:2022
ISO Accredited
HIPAA
All reports reviewed by DHA-Certified physicians